Immuno-Oncology Attracts Big Deal Dollars For Biotechs
This article was originally published in Start Up
Biotechs in the immuno-oncology space can’t operate in a vacuum. To attract funding and partners, their drug candidates must show potential to not only surpass available treatments, but also have the ability to work in tandem with them.
Register for our free email digests: